XML 44 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Share-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity
A summary of the stock option activity under the Company’s equity plans and inducement awards, for the three months ended March 31, 2021 is as follows:
(number of shares in millions)Number
of
Shares		Weighted
Average
Exercise
Price
Options outstanding at December 31, 20205.2 $23.24 
Options granted— $— 
Less:
Options exercised(1.2)$21.83 
Options canceled or expired(0.1)$24.29 
Options outstanding at March 31, 20213.9 $23.66 
Options exercisable at March 31, 20213.3 $25.79 
Schedule of Restricted Stock Unit Activity
A summary of the RSU activity under the Company’s equity plans and inducement awards, including RSU awards with performance metrics, for the three months ended March 31, 2021 is as follows:
(number of shares in millions)Number
of
Shares		Weighted
Average
Grant Date
Fair Value
RSUs outstanding at December 31, 20203.2 $20.56 
RSUs granted1.3 $30.07 
Less:
RSUs vested— $— 
RSUs canceled(0.1)$25.60 
RSUs outstanding at March 31, 20214.4 $23.53 
Schedule of Share-Based Compensation Expense
Share-based compensation expense recognized and included in the condensed consolidated statements of operations and comprehensive loss was allocated as follows:
Three Months Ended
March 31,
(in millions)20212020
Cost of molecular diagnostic testing$0.3 $0.3 
Cost of pharmaceutical and clinical services0.1 0.1 
Research and development expense1.5 1.2 
Selling, general, and administrative expense7.1 5.9 
     Total share-based compensation expense$9.0 $7.5